FDA approves first new sickle cell drug in 20 years

first_img Log In | Learn More Tags drug developmentpolicyrare diseases By Adam Feuerstein July 7, 2017 Reprints About the Author Reprints Senior Writer, Biotech Adam is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He’s also a co-host of “The Readout LOUD” podcast. What’s included? Biotech [email protected] STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. The FDA approved a new medicine Friday to reduce the complications associated with sickle cell disease, a rare blood disorder.The drug, Endari, is made by privately held Emmaus Medical and is the first new treatment for sickle cell disease to secure FDA approval in almost 20 years. However, the active ingredient in Endari — L-glutamine — is an old chemical that can be purchased over the counter, which could complicate Emmaus’s ability to obtain insurance coverage.center_img Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. GET STARTED What is it? @adamfeuerstein Adam Feuerstein FDA approves first new sickle cell drug in 20 years APStock Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. First 30 days free. GET STARTEDlast_img read more

Read More »